Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study

被引：0

作者：

von Amsberg, G. ^{[1
]}

Powles, T. ^{[2
]}

Loriot, Y. ^{[3
]}

Ravaud, A. ^{[4
]}

Vogelzang, N. J. ^{[5
]}

Duran, I. ^{[6
]}

Retz, M. ^{[7
]}

De Giorgi, U. ^{[8
]}

Oudard, S. ^{[9
]}

Bamias, A. ^{[10
]}

Koeppen, H. ^{[11
]}

Leng, N. ^{[11
]}

Kadel, E. E. ^{[11
]}

Hegde, P. S. ^{[11
]}

Cui, N. ^{[11
]}

Shen, X. ^{[11
]}

Green, M. ^{[11
]}

Banchereau, R. ^{[11
]}

Mariathasan, S. ^{[11
]}

van der Heijden, M. S. ^{[12
]}

机构：

[1] Univ Klinikum Hamburg Eppendorf, Ctr Oncol, Hamburg, Germany

[2] Queen Mary Univ London, Barts Canc Inst, London, England

[3] Gustave Roussy, Villejuif, France

[4] Hop St Andre CHU, Bordeaux, France

[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[6] Univ Seville, Inst Biomed Sevilla, Hosp Univ Virgen del Rocio, CSIC, Seville, Spain

[7] Tech Univ Munich, Munich, Germany

[8] IRST IRCCS, Meldola, Italy

[9] Hop Europeen Georges Pompidou, Paris, France

[10] Univ Athens, ALEXANDRA Hosp, Athens, Greece

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] Netherlands Canc Inst, Amsterdam, Netherlands

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P990

引用

页码：325 / 326

页数：2

共 42 条

[1] Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
Powles, Thomas
Loriot, Yohann
Ravaud, Alain
Vogelzang, Nicholas J.
Duran, Ignacio
Retz, Margitta
De Giorgi, Ugo
Oudard, Stephane
Bamias, Aristotelis
Koeppen, Hartmut
Leng, Ning
Kadel, Edward E.
Hegde, Priti S.
Cui, Na
Shen, Xiaodong
Derleth, Christina Louise
Green, Marjorie C.
Banchereau, Romain
Mariathasan, Sanjeev
Van Der Heijden, Michiel Simon
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[2] Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study
Van der Heijden, M. S.
Loriot, Y.
Duran, I.
Ravaud, A.
Retz, M. M.
Vogelzang, N. J.
Nelson, B.
Wang, J.
Shen, X.
Powles, T.
ANNALS OF ONCOLOGY, 2019, 30
[3] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): outcomes by prior therapy
von Amsberg, G.
Perez-Garcia, J. L.
Loriot, Y.
Rosenberg, J. E.
Powles, T.
Necchi, A.
Hussain, S. A.
Morales-Barrera, R.
Retz, M.
Niegisch, G.
Duran, I.
Theodore, C.
Grande, E.
Thastrom, A. C.
Li, S.
Abidoye, O. O.
Van Der Heijden, M. S.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 115 - 115
[4] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Post-progression outcomes from the phase 2 IMvigor210 study
Necchi, A.
Joseph, R. W.
Loriot, Y.
Hoffman-Censits, J.
Perez Gracia, J. L.
Petrylak, D. P.
Zhu, Q.
Ding, B.
Kaiser, C.
Rosenberg, J. E.
ANNALS OF ONCOLOGY, 2017, 28
[5] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.
Perez-Gracia, Jose Luis
Loriot, Yohann
Rosenberg, Jonathan E.
Powles, Thomas
Necchi, Andrea
Hussain, Syed A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[6] Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Powles, Thomas
Duran, Ignacio
van der Heijden, Michiel S.
Loriot, Yohann
Vogelzang, Nicholas J.
De Giorgi, Ugo
Oudard, Stephane
Retz, Margitta M.
Castellano, Daniel
Bamias, Aristotelis
Flechon, Aude
Gravis, Gwenaelle
Hussain, Syed
Takano, Toshimi
Leng, Ning
Kadel, Edward E., III
Banchereau, Romain
Hegde, Priti S.
Mariathasan, Sanjeev
Cui, Na
Shen, Xiaodong
Derleth, Christina L.
Green, Marjorie C.
Ravaud, Alain
LANCET, 2018, 391 (10122): : 748 - 757
[7] Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
van der Heijden, Michiel S.
Loriot, Yohann
Duran, Ignacio
Ravaud, Alain
Retz, Margitta
Vogelzang, Nicholas J.
Nelson, Betty
Wang, Jingjing
Shen, Xiaodong
Powles, Thomas
EUROPEAN UROLOGY, 2021, 80 (01) : 7 - 11
[8] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study.
Bellmunt, Joaquim
Pal, Sumanta K.
Zheng, Hanzhe
Tayama, Darren
Chang, Dannis
Hoffman-Censits, Jean H.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
Hoffman-Censits, Jean H.
Grivas, Petros
Van der Heijden, Michiel Simon
Dreicer, Robert
Loriot, Yohann
Retz, Margitta
Vogelzang, Nicholas J.
Perez-Gracia, Jose Luis
Rezazadeh, Arash
Bracarda, Sergio
Yu, Evan Y.
Hoimes, Christopher J.
Bellmunt, Joaquim
Quinn, David I.
Petrylak, Daniel Peter
Hussain, Syed A.
Cui, Na
Mariathasan, Sanjeev
Abidoye, Oyewale O.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[10] Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
Necchi, A.
Joseph, R. W.
Loriot, Y.
Hoffman-Censits, J.
Perez-Gracia, J. L.
Petrylak, D. P.
Derleth, C. L.
Tayama, D.
Zhu, Q.
Ding, B.
Kaiser, C.
Rosenberg, J. E.
ANNALS OF ONCOLOGY, 2017, 28 (12) : 3044 - 3050

← 1 2 3 4 5 →